Sansure Biotech Announces Over RMB 100 Million in Investments Within Three Days Amid Continued Losses Despite Diversified Strategic Layout

Source: Shell Finance

Beijing News (Reporter Liu Xu) On the evening of March 15,Sansure BiotechSansure Biotech Inc. (hereinafter referred to as "Sansure Biotech") announced that it plans to jointly invest with its related party, Hunan Jinfurong Sansure Bio-Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as the "Fund"), to establish Hunan Sanwei Huasi Biotechnology Co., Ltd. (provisional name, hereinafter referred to as the "Joint Venture"), which will serve as the investment entity for the subsequent acquisition of 100% equity in Huasi Wuyi Microbial Technology (Shenzhen) Co., Ltd. (hereinafter referred to as "Huasi Wuyi"). Among this, Sansure Biotech will contribute a total of 65.438 million yuan from its own funds. After the completion of this transaction, the Joint Venture and Huasi Wuyi will be included in the company's consolidated financial statements.

Vazyme Biotech mainly engages in the research, development, production, and sales of in vitro diagnostic reagents and supporting instruments for human, animal, and pet use (testing targets include but are not limited to nucleic acids, proteins, small molecules, cells, etc.), with proprietary intellectual property rights in infrared fluorescence enhancement technology. The company's current products focus on immunofluorescence and have achieved more than 10 invention and utility model patents in areas such as fluorescent dye molecular design, preparation of fluorescent nanospheres, supporting equipment and consumables for immunofluorescence/immunological diagnostics, and testing applications. The products have obtained more than 20 registration certificates from the National Medical Products Administration in China and over 60 EU CE certifications.

As of December 31, 2025, Huas Wuwei's total assets amounted to RMB 8.539 million, total liabilities reached RMB 20.6382 million, and net assets stood at -RMB 12.0993 million. In the fiscal year 2025, the company achieved operating revenue of RMB 3.2015 million and a net profit of -RMB 6.914 million.

Sansure Biotech stated that infrared fluorescence enhancement technology is a key technology in in vitro diagnostics (IVD) that improves detection performance by amplifying near-infrared light signals. It can significantly enhance the sensitivity and accuracy of testing. This technology is driving the entire IVD industry towards ultra-sensitivity and deep penetration, serving as an important cornerstone for breakthrough advancements in high-end immunoassays, molecular diagnostics, and precision medicine. The core business of Wasimum revolves around infrared fluorescence enhancement technology, pioneering POCT detection technology based on infrared fluorescent nanobeads. Wasimum's operations can achieve strong synergy with the company’s existing business. Upon completion of this investment, it will further enhance the company’s industrial layout.

This is the second investment by Sansure Biotech within three days. On March 13, Sansure Biotech announced that it plans to jointly invest in PHIL RIVERS TECHNOLOGY Co., Ltd. ("PHIL RIVERS") with its related party, Hunan Jinfurong Sansure Bio-equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as the "Fund"). Among the investment, the company will invest 40 million yuan from its own funds, and the Fund will invest 50 million yuan. After the equity transfer and capital increase transactions, the company will hold 4.02% of PHIL RIVERS' shares.

PHIL RIVERS is a platform company that empowers pharmaceutical innovation with digital life technology. Its core technology platform is a knowledge graph built on massive amounts of publicly available literature and biomedical research data. Sansure Biotech stated that this investment will enhance the company's industrial chain layout in the "AI + healthcare" field.

Sansure Biotech is a leading enterprise in the molecular diagnostics industry. During the COVID-19 pandemic, its developed SARS-CoV-2 nucleic acid test kit was approved on January 28, 2020, making it one of the first six companies in China to have such products approved for market launch. In August 2020, basking in the glory of being known as the "first stock of the anti-epidemic effort," Sansure Biotech Inc. was listed on the STAR Market.

After the COVID-19 nucleic acid test kit hit the market, the revenue of Sansure Biotech surged from less than 400 million yuan. From 2020 to 2022, its revenues reached 4.763 billion yuan, 4.515 billion yuan, and 6.45 billion yuan respectively, with net profits of 2.617 billion yuan, 2.243 billion yuan, and 1.937 billion yuan respectively. At the end of 2022, China's public health prevention and control policies underwent significant changes. Without the support of the COVID-19 business, Sansure Biotech's performance plummeted. In 2023, its operating revenue and net profit attributable to shareholders were 1.007 billion yuan and 364 million yuan respectively, representing year-on-year declines of 84.39% and 81.22%.

Sansure Biotech has also been seeking new growth points for its performance. In the 2022 annual report, Sansure Biotech proposed a "second entrepreneurship," embarking on an acquisition spree. In 2023, Sansure Biotech invested 171 million yuan with related parties to establish Hunan Sansure Ansa Biotechnology Co., Ltd., enhancing its layout in the field of immuno-diagnostic chemiluminescence. In 2024, it invested another 123 million yuan with related parties to set up Hunan Saintmicro Rapid Sensitivity Biotechnology Co., Ltd., focusing on rapid antibiotic susceptibility testing. In January 2025, Sansure Biotech acquired 100% equity of Zhongshan Weiming Haiji Biomedical Co., Ltd. for 807.5 million yuan, expanding into the growth hormone sector. In February 2025, it obtained 54% equity of Changsha Red Bank Base Biological Technology Co., Ltd., entering the hematology analyzer POCT field. In March 2025, the company spent another 130 million yuan through equity transfer and capital increase, raising its stake in Genemind Biotech from 11.90% to 15.55%. In May 2025, Sansure Biotech injected 100 million yuan into Hunan Saintway Kunpeng Biotechnology Co., Ltd.

Under a multi-line layout, Sansure Biotech's operating revenue has achieved growth for two consecutive years, but the net profit attributable to shareholders continues to decline. In 2025, Sansure Biotech achieved an operating revenue of 1.648 billion yuan, a year-on-year increase of 13.04%; the net profit attributable to shareholders of the listed company was 198 million yuan, a year-on-year decrease of 28.10%. In this regard, Sansure Biotech stated that in 2025, the VAT rate for domestically produced diagnostic reagents in the in vitro diagnostics industry increased from 3% to 13%. Coupled with the gradual advancement of China's centralized procurement policy, product prices were pressured, significantly impacting the company’s profits. Additionally, the company increased its investment in R&D and innovation and promoted strategic mergers and acquisitions integration. The increase in related investments diluted profits in the short term.

Proofread by Baoqing Liu